Impax Laboratories Inc

Impax Laboratories — J.P. Morgan Healthcare Conference 2010

29 slides from Impax Laboratories's conference presentation, Jan 12, 2010

  1. Slide 1: J.P. Morgan Healthcare Conference January 11, 2010

    Slide 1: J.P. Morgan Healthcare Conference January 11, 2010

    J.P. Morgan Healthcare Conference January 11, 2010

  2. Slide 2: Safe Harbor Statement

    Slide 2: Safe Harbor Statement

    Safe Harbor Statement "Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: To the extent any statements made in this presentation contain information that is not historical, these statements are forward-looking in nature and express the beliefs and expectations of mana

  3. Slide 3: Strong Platform for Long Term Growth

    Slide 3: Strong Platform for Long Term Growth

    Complex formulation development and manufacturing Balanced business model Track record of performance Substantial pipeline of new products Strong Platform for Long Term Growth Generic Unique Targeted High Value ANDAs Brand Offering Long-Term Growth Drivers

  4. Slide 4: Dual Strategic Focus

    Slide 4: Dual Strategic Focus

    Dual Strategic Focus Unique targeted ANDAs First-to-file, First-to-market Limited competition Difficult to formulate and manufacture 31 apps pending at FDA 52 under development CNS Products Improve on marketed products 505(b)(2) NDA candidates Develop IP positions 2 products in Phase III 3 in explor

  5. Slide 5: Generic Products Division

    Slide 5: Generic Products Division

    Generic Products Division | » GLOBAL Le PHARMACEUTICALS

  6. Slide 6: Solid Year to Date Generic Performance

    Slide 6: Solid Year to Date Generic Performance

    YTD Sep '08 YTD Sep '09 Other 14.5 18.9 RX Partner 72.1 30.2 Global 69 123.1 Solid Year to Date Generic Performance $156 $172 Nine months ended - $ millions Global products RX Partner Other "Growing Higher Margin Global Products Segment Revenue"

  7. Slide 7: Generic Growth Initiatives

    Slide 7: Generic Growth Initiatives

    Generic Growth Initiatives Product Development Partnerships Acquisition (Product or Company) Global Market Alternate Dosage Forms Internal R&D Unique Targeted High Value ANDAs

  8. Slide 8: Internal Generic Development Expertise

    Slide 8: Internal Generic Development Expertise

    Internal Generic Development Expertise KV Actavis/Abrika Sandoz/Lek Mylan Watson/Andrx Teva/Ivax/Barr 9 10 15 15 19 19 27 Solid position relative to peers Controlled Release Products Approved from 2001 to 2009

  9. Slide 9: 2009 Product Disclosures

    Slide 9: 2009 Product Disclosures

    2009 Product Disclosures Goal 8 to 10 new applications 2 to 3 of these First-to-File or First-to-Market opportunities Results to Date 8 new applications submitted and accepted for filing ....More to come Products Disclosed to Date Tricor(r) - Fenofibrate Tablets, 48mg and 145mg Oracea(r) - Doxycycli

  10. Slide 10: Products Pending or Under Development

    Slide 10: Products Pending or Under Development

    83 Products Pending or Under Development Currently Marketed ANDAs Pipeline East 47 26 44 41 31 52 Present Future = 83 Products in Pipeline Pending at FDA = $17B Under Development = $15B - - 53% controlled release products $32B U.S. Brand/ Generic Sales

  11. Slide 11: Disclosed ANDA Pending Pipeline

    Slide 11: Disclosed ANDA Pending Pipeline

    Disclosed ANDA Pending Pipeline First-to-File Products LTM Brand Sales LTM Brand Sales Sevelamer Carbonate (Renvela(r)) 800mg Sevelamer Carbonate (Renvela(r)) 800mg $143MM Doxycycline Hyclate DR (Doryx(r)) 150mg Doxycycline Hyclate DR (Doryx(r)) 150mg $220MM Doxycycline Hyclate DR (Doryx(r)) 75, 100

  12. Slide 12: Development Pipeline

    Slide 12: Development Pipeline

    Development Pipeline Total Under Development 52 $15B * Brands not yet launched or sales data not yet available Unique Targeted High Value ANDAs First-to-File/First-to-Market # of Products Brand Sales Potential First-to-File 12 $1B Potential First-to-File 19 N/A* Other ER/IR Products 21 $14B Focused

  13. Slide 13: Substantial and Growing Manufacturing Capacity

    Slide 13: Substantial and Growing Manufacturing Capacity

    Substantial and Growing Manufacturing Capacity Taiwan 600 million unit annual capacity with potential to add additional capacity in the future Fully approved and operational early 2010 Hayward, CA 1.2 billion unit annual capacity Product exported back to U.S. Philadelphia Packaging facility

  14. Slide 14: Brand Products Division

    Slide 14: Brand Products Division

    Brand Products Division CID IMPAX

  15. Slide 15: Impax Pharmaceuticals Background

    Slide 15: Impax Pharmaceuticals Background

    Impax Pharmaceuticals Background Therapeutic focus: Central Nervous System Formulation expertise lays the foundation Controlled-release formulation technologies Broad drug delivery technologies Focus on unmet therapeutic needs Develop IP positions around selected products 505(b)(2) Drug Applications

  16. Slide 16: Brand Growth Initiatives

    Slide 16: Brand Growth Initiatives

    Brand Growth Initiatives In-license (Products) Acquisition (Products or Companies) Co-promotion Co-development with Co-marketing Rights Internal R&D Programs Promotion For Pfizer "Driving to Financial Self-Support"

  17. Slide 17: IPX066: Parkinson's Disease

    Slide 17: IPX066: Parkinson's Disease

    IPX066: Parkinson's Disease European Union United States Japan 1.1 1 0.2 Parkinson's Disease Major Market Prevalence (in millions) Background Affects as many as 1-2% of persons aged 60 and older Over 2 million people in US, Europe and Japan Symptoms are motor and non- motor in nature

  18. Slide 18: IPX066 Potential Benefits

    Slide 18: IPX066 Potential Benefits

    IPX066 Potential Benefits Reduction in "Off" time Reduced dosing frequency Increase "On" time without troublesome dyskinesia Improvement in quality of life Predictability of "On" time Controlled-release Carbidopa/Levodopa Addresses certain limitations of current Levodopa therapy IPX066: Parkinson's

  19. Slide 19: IPX066: Development Status

    Slide 19: IPX066: Development Status

    Naive Patients APEX-PD STARTED APRIL 2009 Advanced Patients ADVANCE-PD STARTED SEPTEMBER 2009 PRECLINICAL & POC PHASE I PHASE II PHASE III NDA SUBMISSION COMPLETED COMPLETED COMPLETED 4Q 2011 Preliminary data - 1Q 2011 Final Data - 1H 2011 IPX066: Development Status

  20. Slide 20: IPX066: Positive Phase II Results

    Slide 20: IPX066: Positive Phase II Results

    IPX066: Positive Phase II Results - -2.5 - -2 - -1.5 - -1 - -0.5 0 0.5 1 1.5 2 2.5 Change from Baseline (Hours) ^ in OFF P<0.0001 ^ in ON P=0.002 Dosing Frequency P<0.0001 3.5 doses/day 5.4 doses/day IPX066 IR CD-LD Greater reduction in "Off" time Increase in "On" time Less frequent dosing

  21. Slide 21: IPX066 - Phase II Results Summary

    Slide 21: IPX066 - Phase II Results Summary

    IPX066 - Phase II Results Summary Clinical Efficacy Reduction of "OFF" time Increase of "ON" time without troublesome dyskinesias Improvement of motor symptom control Enhanced dosing convenience 0 2 4 6 8 10 12 14 IPX066 IR CD-LD Change from Baseline in %"OFF" Time During Waking Hours Improved QOL f

  22. Slide 22: IPX066 - Naive PD Patient Phase III Study

    Slide 22: IPX066 - Naive PD Patient Phase III Study

    IPX066 - Naive PD Patient Phase III Study Randomized, double-blind, placebo-controlled, fixed-dose, parallel arm study of 3 doses of IPX066 vs. placebo North America and Europe 350 subjects - target enrollment 30-week treatment duration Primary endpoint: change from baseline in the sum of UPDRS Part

  23. Slide 23: IPX066 - Advanced PD Patient Phase III Study

    Slide 23: IPX066 - Advanced PD Patient Phase III Study

    IPX066 - Advanced PD Patient Phase III Study Randomized, double-blind, active-control, parallel-group comparison of IPX066 vs. IR carbidopa-levodopa North America and Europe 420 subjects - target enrollment 22-week treatment duration Primary endpoint: percentage of "Off" time during waking hours

  24. Slide 24: IPX056 Status

    Slide 24: IPX056 Status

    IPX056 Status Spasticity in Multiple Sclerosis Product type: Controlled-release Baclofen Baclofen is drug of choice in treating spasticity Significant unmet need for product offering reduced nocturnal spasticity, less morning stiffness, improved control, and dosing convenience Completed first succes

  25. Slide 25: Financial Update

    Slide 25: Financial Update

    improving Health Through Technology QD IMPAX Financial Update

  26. Slide 26: Healthy Financial Position - No Debt!

    Slide 26: Healthy Financial Position - No Debt!

    Healthy Financial Position - No Debt! 4Q07 1Q08 2Q08 3Q08 4Q08 1Q09 2Q09 3Q09 Cash & Short-term investments 109.704 136.571 118.101 81.152 119.985 98.355 103.27 100.527 Accounts receivable net of debt -33.792 2.153 -36.702 17.249 22.9 41.746 46.578 61.543 Increasing Liquidity

  27. Slide 27: 2010 Financial Outlook

    Slide 27: 2010 Financial Outlook

    2010 Financial Outlook Improved top-line performance driven by generic division products: Significant variability depending on: Generic Adderall XR(r) Citizen Petition status Generic Flomax(r) competitive landscape Gross margins expected in ~ 50% range Expense control is critical management objectiv

  28. Slide 28: 2010 Financial Outlook

    Slide 28: 2010 Financial Outlook

    2010 Financial Outlook Expense Item Outlook Total R&D Approximately $77 million Generic R&D Approximately $41 million Brand R&D Approximately $36 million Litigation Approximately $11 million S, G & A Approximately $50 million Other Outlook Tax rate Low 40% range(1) Capital expenditures Approximately

  29. Slide 29: Strong Platform for Long Term Growth

    Slide 29: Strong Platform for Long Term Growth

    Complex formulation development and manufacturing Balanced business model Track record of performance Substantial pipeline of new products Strong Platform for Long Term Growth Generic Unique Targeted High Value ANDAs Brand Offering Long-Term Growth Drivers

Source: SEC EDGAR · 8-K filed Jan 12, 2010

More decks from Impax Laboratories Inc